RBPJ and melanoma: Compared with murine RBP-J+/− DCs, RBP-J−/− DCs (specific knockout of RBP-J in DCs) lost inhibition of tumors (e.g., B16F10 melanoma, H22 hepatoma, and Lewis lung carcinoma) in vivo because DC migration and antigen presentation to T cells were inhibited [9].